Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2009, Article ID 179350, 5 pages
http://dx.doi.org/10.4061/2009/179350
Review Article

Heart Rate and Cardiovascular Disease: An Alternative to Beta Blockers

Department of Cardiology, Waikato Hospital, Pembroke & Selwyn Sts, Private Bag 3200, Hamilton 3240, New Zealand

Received 28 April 2009; Accepted 13 July 2009

Academic Editor: Jalal K. Ghali

Copyright © 2009 Michael Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Kannel, C. Kannel, R. S. Paffenbarger Jr., and A. Cupples, “Heart rate and cardiovascular mortality: the Framingham study,” American Heart Journal, vol. 113, no. 6, pp. 1489–1494, 1987. View at Google Scholar
  2. R. F. Gillum, D. M. Makuc, and J. J. Feldman, “Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study,” American Heart Journal, vol. 121, no. 1, pp. 172–177, 1991. View at Publisher · View at Google Scholar
  3. K. Fox, J. S. Borer, A. J. Camm et al., “Resting heart rate in cardiovascular disease,” Journal of the American College of Cardiology, vol. 50, no. 9, pp. 823–830, 2007. View at Publisher · View at Google Scholar
  4. P. Palatini and S. Julius, “Elevated heart rate: a major risk factor for cardiovascular disease,” Clinical and Experimental Hypertension, vol. 26, no. 7-8, pp. 637–644, 2004. View at Publisher · View at Google Scholar
  5. P. Palatini, E. Casiglia, P. Pauletto, J. Staessen, N. Kaciroti, and S. Julius, “Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations,” Hypertension, vol. 30, no. 5, pp. 1267–1273, 1997. View at Google Scholar
  6. G. D. Giannoglou, Y. S. Chatzizisis, C. Zamboulis, G. E. Parcharidis, D. P. Mikhailidis, and G. E. Louridas, “Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms,” International Journal of Cardiology, vol. 126, no. 3, pp. 302–312, 2008. View at Publisher · View at Google Scholar
  7. A. Perski, A. Hamsten, K. Lindvall, and T. Theorell, “Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients,” American Heart Journal, vol. 116, no. 5, pp. 1369–1373, 1988. View at Google Scholar
  8. M. Pfisterer, P. Buser, S. Osswald et al., “Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial,” Journal of the American Medical Association, vol. 289, no. 9, pp. 1117–1123, 2003. View at Publisher · View at Google Scholar
  9. A. Diaz, M. G. Bourassa, M.-C. Guertin, and J.-C. Tardif, “Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease,” European Heart Journal, vol. 26, no. 10, pp. 967–974, 2005. View at Publisher · View at Google Scholar
  10. R. Kolloch, U. F. Legler, A. Champion et al., “Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/ trandolapril STudy (INVEST),” European Heart Journal, vol. 29, no. 10, pp. 1327–1334, 2008. View at Publisher · View at Google Scholar
  11. K. Fox, I. Ford, P. G. Steg, M. Tendera, M. Robertson, and R. Ferrari, “Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial,” The Lancet, vol. 372, no. 9641, pp. 817–821, 2008. View at Publisher · View at Google Scholar
  12. M. Tendera, “If inhibition: from pure heart reduction to treatment of stable angina,” European Heart Journal, Supplement, vol. 7, supplement H, pp. H3–H6, 2005. View at Publisher · View at Google Scholar
  13. R. Ferrari, G. Campo, E. Gardini, G. Pasanisi, and C. Ceconi, “Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients,” European Heart Journal, Supplement, vol. 7, supplement H, pp. H16–H21, 2005. View at Publisher · View at Google Scholar
  14. J. Kjekshus and L. Gullestad, “Heart rate as a therapeutic target in heart failure,” European Heart Journal, Supplement, vol. 1, supplement H, pp. H64–H69, 1999. View at Google Scholar
  15. S. Holt and R. Beasley, “The Burden of Asthma in New Zealand. Report produced for the Asthma and Respiratory Foundation of New Zealand,” December 2001. View at Google Scholar
  16. H. F. Brown, D. DiFrancesco, and S. J. Noble, “How does adrenaline accelerate the heart?” Nature, vol. 280, no. 5719, pp. 235–236, 1979. View at Google Scholar
  17. C. Altomare, B. Terragni, C. Brioschi et al., “Heteromeric HCN1-HCN4 channels: a comparison with native pacemaker channels from the rabbit sinoatrial node,” Journal of Physiology, vol. 549, no. 2, pp. 347–359, 2003. View at Google Scholar
  18. D. DiFrancesco and J. S. Borer, “The funny current: cellular basis for the control of heart rate,” Drugs, vol. 67, supplement 2, pp. 15–24, 2007. View at Google Scholar
  19. Y. Ogiwara, Y. Furukawa, K. Akahane, M. Haniuda, and S. Chiba, “Bradycardic effects of AQ-A 39 (Falipamil) in situ and in isolated, blood-perfused dog hearts. Comparison with alinidine and verapamil,” Japanese Heart Journal, vol. 29, no. 6, pp. 849–861, 1988. View at Google Scholar
  20. W. H. Frishman, C. J. Pepine, R. J. Weiss, and W. M. Baiker, “Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study,” Journal of the American College of Cardiology, vol. 26, no. 2, pp. 305–312, 1995. View at Publisher · View at Google Scholar
  21. W. H. Frishman, A. Retter, J. Misailidis et al., “Innovative pharmacologic approaches to treatment of myocardial ischemia,” in Cardiovascular Pharmacotherapies, W. H. Frishman, E. H. Sonnenblick, and D. A. Sica, Eds., pp. 655–690, McGraw-Hill, New York, NY, USA, 2nd edition, 2003. View at Google Scholar
  22. C. Thollon, C. Cambarrat, J. Vian, J.-F. Prost, J. L. Peglion, and J. P. Vilaine, “Electrophysiological effects of S 16257 a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49,” British Journal of Pharmacology, vol. 112, no. 1, pp. 37–42, 1994. View at Google Scholar
  23. K. Fox, I. Ford, P. G. Steg, M. Tendera, and R. Ferrari, “Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 372, no. 9641, pp. 807–816, 2008. View at Publisher · View at Google Scholar
  24. C. Thollon, J.-P. Bidouard, C. Cambarrat et al., “Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257,” European Journal of Pharmacology, vol. 339, no. 1, pp. 43–51, 1997. View at Publisher · View at Google Scholar
  25. D. DiFrancesco and J. A. Camm, “Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease,” Drugs, vol. 64, no. 16, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar
  26. J.-C. Tardif, I. Ford, M. Tendera, M. G. Bourassa, and K. Fox, “Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina,” European Heart Journal, vol. 26, no. 23, pp. 2529–2536, 2005. View at Publisher · View at Google Scholar
  27. W. Ruzyllo, I. F. Ford, M. T. Tendera et al., “On behalf of the study investigators. Anti-anginal and anti-ischaemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial,” European Heart Journal, vol. 25, supplement, p. 138, 2004. View at Google Scholar
  28. J. S. Borer, K. Fox, P. Jaillon, and G. Lerebours, “Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial,” Circulation, vol. 107, no. 6, pp. 817–823, 2003. View at Publisher · View at Google Scholar
  29. W. Ruzyllo, I. F. Ford, M. T. Tendera et al., “On behalf of the study investigators. Anti-anginal and anti-ischaemic effects of the If current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. Randomised, controlled, double-blind trial,” European Heart Journal, vol. 25, supplement, p. 138, 2004. View at Google Scholar
  30. L. Lopez-Bescos, S. Filipova, and R. Martos, “On behalf of the study investigators. Long-term safety and anti-anginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. A one year randomised, double-blind, multicentre trial,” European Heart Journal, vol. 25, supplement 1, p. 138., 2004. View at Google Scholar